MBOTHIGH SIGNALFINANCIAL10-K

MBOT underwent massive equity dilution with shares outstanding nearly doubling from 35M to 67M while achieving dramatic balance sheet improvement through what appears to be a large equity raise.

The company raised substantial capital (likely $70M+) that transformed its financial position from cash-starved to well-capitalized, but existing shareholders suffered severe dilution of approximately 48%. While this addresses the critical going concern risks and provides runway for operations, the dilution represents a significant wealth transfer from existing to new shareholders.

Comparing 2026-03-26 vs 2025-03-25View on EDGAR →
FINANCIAL ANALYSIS

MBOT's financial transformation was dramatic across all metrics, with total assets growing 1,252% to $81.5M and stockholders' equity surging 2,097% to $77.6M, clearly indicating a major equity financing event. While revenue tripled to $117K showing operational progress, operating losses worsened 48% to -$13M and SG&A expenses increased 69% to $8.5M, suggesting higher burn rates despite the improved cash position. The massive capital infusion provides financial stability but comes at the cost of substantial shareholder dilution, fundamentally altering the company's capital structure.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+2097%
$3.5M$77.6M

Equity base grew 2097% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+1271.7%
$5.8M$79.8M

Current assets grew 1271.7% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+1252.1%
$6.0M$81.5M

Asset base grew 1252.1% — expansion through organic growth, acquisitions, or capital deployment.

Revenue
P&L
+215.9%
$37K$117K

Strong top-line growth of 215.9% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
+140%
$25K$60K

Capital expenditure jumped 140% — major investment cycle underway; assess returns on deployment.

SG&A Expense
P&L
+69.4%
$5.0M$8.5M

SG&A up 69.4% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Total Liabilities
Balance Sheet
+59.5%
$2.5M$4.0M

Liabilities grew 59.5% — significant increase in debt or obligations, assess impact on financial flexibility.

Operating Cash Flow
Cash Flow
-47.8%
-$8.8M-$13.0M

Operating cash flow fell 47.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Accounts Receivable
Balance Sheet
+46.5%
$109K$159K

Receivables surged 46.5% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Current Liabilities
Balance Sheet
+39.1%
$2.5M$3.4M

Current liabilities surged 39.1% — significant near-term obligations; verify ability to meet short-term debt.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-25
ADDED
Common stock outstanding as of March 24, 2026: 67,158,044 shares INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements.
Exhibits and Financial Statement Schedules 53 Item 16 Form 10-K Summary 55 i NOTE REGARDING REFERENCES TO OUR COMPANY Throughout this Form 10-K, the words we, us, our, the Company and Microbot refer to Microbot Medical Inc., including our wholly owned subsidiary, Microbot Medical Ltd., an Israeli corporation ( Microbot Israel ).
Unless the context otherwise requires, the historical business, financial statements and operations of Microbot include Microbot Israel, which became a wholly owned subsidiary of the Company on November 28, 2016.
Risks Relating to Microbot s Financial Position and Need for Additional Capital Through December 31, 2025, Microbot has not recognized any revenues, and cannot make any assurances of generating significant revenues in the future.
It has incurred significant operating losses since inception and is expected to continue to incur significant operating losses for the foreseeable future.
+7 more — sign up free →
REMOVED
Common stock outstanding as of March 24, 2025: 34,744,476 shares INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements.
Exhibits and Financial Statement Schedules 55 Item 16 Form 10-K Summary 57 i NOTE REGARDING REFERENCES TO OUR COMPANY Throughout this Form 10-K, the words we, us, our, the Company and Microbot refer to Microbot Medical Inc., including our directly and indirectly wholly owned subsidiary.
Unless the context otherwise requires, the historical business, financial statements and operations of Microbot include Microbot Medical Ltd., an Israeli corporation ( Microbot Israel ) which became a wholly owned subsidiary of the Company on November 28, 2016.
Risks Relating to Microbot s Financial Position and Need for Additional Capital Microbot has had no revenue and has incurred significant operating losses since inception and is expected to continue to incur significant operating losses for the foreseeable future.
Microbot has a limited operating history outside of being a research and development-stage company, which may make it difficult to evaluate the prospects for the Company s future viability.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →